Floatz logo

Lonafarnib

Metastatic Malignant Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

276 Active assets in the Metastatic Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Lonafarnib is also rated in:

Hutchinson-Gilford progeria syndromeDormant
B
Indicative ·
58 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →